Vascular Biogenics (NASDAQ:VBLT) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Vascular Biogenics (NASDAQ:VBLT – Get Rating) in a report released on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Vascular Biogenics Stock Performance

Shares of NASDAQ:VBLT opened at $0.24 on Wednesday. The company has a 50 day moving average price of $0.20 and a 200 day moving average price of $0.16. The stock has a market capitalization of $16.95 million, a price-to-earnings ratio of -0.76 and a beta of 0.68. Vascular Biogenics has a 1-year low of $0.10 and a 1-year high of $2.20.

Get Vascular Biogenics alerts:

Vascular Biogenics (NASDAQ:VBLT – Get Rating) last announced its earnings results on Tuesday, March 14th. The biopharmaceutical company reported ($0.05) EPS for the quarter. Vascular Biogenics had a negative return on equity of 96.11% and a negative net margin of 4,465.93%.

Institutional Trading of Vascular Biogenics

Several large investors have recently added to or reduced their stakes in VBLT. Advisor Group Holdings Inc. lifted its stake in Vascular Biogenics by 49.2% in the 1st quarter. Advisor Group Holdings Inc. now owns 36,797 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 12,133 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in Vascular Biogenics during the first quarter valued at approximately $64,000. Group One Trading L.P. increased its stake in Vascular Biogenics by 62.0% in the 3rd quarter. Group One Trading L.P. now owns 293,118 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 112,148 shares during the period. Telemetry Investments L.L.C. lifted its position in Vascular Biogenics by 239.0% in the 3rd quarter. Telemetry Investments L.L.C. now owns 400,000 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 282,000 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Vascular Biogenics during the 3rd quarter valued at $52,000. 4.81% of the stock is owned by institutional investors and hedge funds.

Vascular Biogenics Company Profile

(Get Rating)

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd.

Further Reading

• Get a free copy of the StockNews.com research report on Vascular Biogenics (VBLT)
• As Peloton Shares Fall Over 90%, A Comeback Strategy Surges
• Inflation, The Fed, And The Summer Rally 
• How to Trade Stocks Online the Right Way
• SentinelOne Stock is Down, But Is it Out?
• Oracle Has Spoken: The AI Cloud Is Bigger And Growing Faster

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.